Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of salmeterol bronchodilation on the autonomic nervous system in COPD
2011-001581-18Phase 4Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of salmeterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Immediate effect of inhaled salmeterol on muscle sympathetic nerve activity versus placebo. Started Nov 2011; status: completed.
02
Drugs
salmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-001581-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001581-18.